https://www.eventscribe.com/2020/painweek/images/painweek-favicon.ico Full Schedule Skip to main content


Icon Legend
This session is not in your agenda.
This session is in your agenda. Click to remove it

Full Schedule

Full Schedule

  • Cancelled
  • 60-Day PNS Treatment May Improve Identification of False-positive and False-negative Responders
  • A Digital Platform to Enable Longitudinal Remote Patient Monitoring Confers a Reduction in Medication Utilization
  • A Long-term Assessment of the Safety, Tolerability, and Durability of an Office-based, Pharmacist-directed Approach to Treatment with Medical Cannabis for Chronic Pain
  • A Needle in a Haystack: OTC Analgesics in Our Opioid Crisis
  • A NEW WEARABLE TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION DEVICE (ACTITENS®) IS MORE EFFICIENT AND BETTER TOLERATED THAN WEAK OPIOIDS IN THE TREATMENT OF KNEE OSTEOARTHRITIS PAIN. RESULTS OF A RANDOMIZED, CONTROLLED, NON-INFERIORITY TRIAL.
  • A THC/CBD oro-buccal spray with improved mucosal absorption and preliminary efficacy for chronic pain.
  • Abuse and misuse of XTAMPZA® ER relative to other opioid analgesics
  • Abuse of tapentadol compared to other atypical opioids among individuals entering treatment for opioid use disorders
  • ALTO-ED: Initiation of a Multidisciplinary SAMSHA Grant Funded Opioid Use Reduction Program in Two Public Health System Emergency Departments
  • Analgesic Combinations in Fixed and Loose Dose
  • Analgesic efficacy and safety of naproxen sodium versus hydrocodone/acetaminophen in acute postsurgical dental pain: a randomized, double-blind, placebo-controlled trial
  • Approved OIC Medication Use in Emergency Department Patients With Opioid-Induced Constipation
  • Assessing Provider Ratings of Satisfaction and Usefulness of the VEGA HCP report – virtual visit
  • At-Home Virtual Reality Program for Chronic Low Back Pain: Double-Blind, Randomized, Placebo-Controlled Trial
  • Atogepant 60 mg Once-Daily Shows Efficacy for the Preventive Treatment of Migraine: Results From a 52-Week Open-Label Extension Trial
  • Atypical chest pain in Carpal Tunnel Syndrome: A Case Report
  • Buprenorphine Buccal Film Versus Oral Oxycodone: Effects on Pupillometry and Respiratory Depression in a Phase 1 Placebo-Controlled Trial
  • Buprenorphine Buccal Film Versus Oral Oxycodone: Secondary Respiratory, Pharmacokinetic, and Pupillometry Outcomes From a Phase 1 Placebo-Controlled Trial
  • CBD for the Treatment of Pain, Sleep, and Anxiety: An Interim Analysis of the SELECT Study
  • Characteristics of Patients Significantly Impacted by Migraine Presenting in Primary Care but Not for Migraine: Results of the OVERCOME (US) Study
  • COmbining UbRogepAnt and preventives for miGrainE (COURAGE) study using the Migraine Buddy application: A novel, entirely remote design for collecting real-world evidence
  • Comparison of treatment impact of high concentration capsaicin topical system (QUTENZA®) and oral pregabalin on patient reported outcomes.
  • Complex Dependency in High-Risk Cancer Patients
  • Cryoneurolysis via a Deep Genicular Approach to Reduce Chronic Knee Pain in Osteoarthritis: A Case Series
  • Daily Atogepant for the Preventive Treatment of Migraine Increases Responder Rates for Reduction in Mean Monthly Migraine Days
  • Diagnosis and treatment satisfaction of common pain in urban China: a population-based cross-sectional National Health and Wellness Survey
  • Diversion and street price of XTAMPZA® ER relative to other prescription opioids
  • Economic burden of chronic pain in China
  • Effects of Tolperisone on Driving Performance, Drowsiness, and Cognitive Function: Comparison With Cyclobenzaprine and Placebo in a Phase 1, Randomized, 4-Period, Crossover Study
  • Efficacy of a Mind-Body Intervention on Post-High Intensity Exercise Pain in Patients with Fibromyalgia
  • Enkephalin as a Potential Analgesic and CNS Modulator
  • Evaluating the Impact of Interprofessional Teams to Decrease Opioid Risk in a Veteran Population
  • Evaluation of the impact of oral naloxone for opioid induced constipation on opioid demand and analgesia in trauma surgery patients
  • Exploratory Efficacy of INP104 by Migraine Attack Severity and Time of Dosing: Results From the Phase 3 STOP 301 Study
  • FAMILY BURDEN ASSOCIATED WITH PRESCRIPTION NSAID AND OPIOID TREATMENT IN PATIENTS WITH OSTEOARTHRITIS
  • How to improve pain scores and quality of life in chronic pain patients
  • Impact of Limiting Short-Acting Opioids on Chronic Pain Management in Veterans at VA Loma Linda
  • Improvements in Disability and the Interictal Period with INP104: Results from the Phase 3 STOP 301 Study
  • Is There a Role for Transdermal Buprenorphine to Manage Acute Pain in the Clinical Setting?
  • L-Methylfolate as an Adjunctive Therapy in Diabetic Peripheral Neuropathy
  • Long COVID and Challenges to the Post-Pandemic World
  • Long-term Safety and Tolerability of Atogepant 60 mg Following Once Daily Dosing Over 1 Year for the Preventive Treatment of Migraine
  • Machine Learning Algorithms in Prediction of the Patient Classification with Moderate-to-Severe Osteoarthritis of the Hip and/or Knee and Inadequate/Intolerable Response to Multiple Pain Medications
  • Managing Severe Pain of Hospice Patients on Admission
  • MAT outcomes during COVID19 at rural clinics
  • Medical Cannabis as Adjunctive Treatment for Chronic Non-cancer Pain (CNCP) to Reduce High Opioid Doses & Optimize Pain Control
  • Meloxicam IV for the Management of Pain Following Radiofrequency Ablation (RFA) of the Spine: A Case Study
  • Mental Health Predictors of Response to Standard Medical Treatment in an Active Duty Military Pain Specialty Clinic
  • Naloxegol Provided Rapid and Sustained Improvement of Opioid-Induced Constipation (OIC) Symptoms in Older Adults Age ≥ 65 Yrs: A Pooled Analysis of Two Phase 3 Studies
  • Naloxegol Provided Rapid Onset of Time to First Spontaneous Bowel Movement (SBM), Complete SBM and Predictable Efficacy in Older Adults (Age ≥ 65 Yrs): A Pooled Analysis of Two Phase 3 Studies
  • Naloxegol Provides Rapid and Sustained Improvement of Opioid-Induced Constipation (OIC) Symptoms Irrespective of Opioid Dose: A Pooled Analysis of Two Phase 3 Studies
  • Non-Medical Use and Diversion of XTAMPZA ER in the General Population
  • Novel approach for sacral root stimulation as a treatment for chronic pelvic pain in females
  • Opioid Prescribing Patterns in an Emergency Department at a Veterans Affairs Hospital
  • Opioid Stewardship Really WoRx: Leveraging the Electronic Health Record to Support Safe and Appropriate Opioid Use
  • Pain Catastrophizing in Individuals with Poly-trauma and Chronic Pain: Contribution to Activity Limitations
  • Pain Management Documentation Review of a Long-Term Care Facility
  • Painful diabetic peripheral neuropathy: the impact on the patient
  • Patient Acceptability of INP104 Aligns With the Unmet Needs Identified in the I-BEAM Survey
  • Patient clinical characteristics and treatment utilization among patients with migraine initiating self-injectable calcitonin gene-related peptide monoclonal antibody and novel acute medication
  • Patterns of Prescription Nonsteroidal Anti-Inflammatory Drug (NSAID) Use Among Osteoarthritis Patients in the United States: Real World Evidence
  • Patterns of viral arthropathy / myalgia with the SARS-CoV-2 epidemic
  • Personalized Pain Therapy: An Artificial Intelligence (AI) Method and Web-Tool to Predict Patient Response to OTC Topical Analgesics
  • Pooled Analysis of the Efficacy of Fremanezumab for Reducing Disability and Acute Medication Overuse in Migraine Patients Overusing Migraine-specific Acute Medications at Baseline
  • Presumptive Versus Definitive Drug Testing: What Are We Missing
  • Primary Headache Disorders and Acute Medications Associated With Patients Diagnosed With Medication Overuse Headache: Analysis of US Claims Data
  • Process of the application of Qutenza (Capsaicin 8%) topical patches for diabetic neuropathy
  • Prolotherapy: A Palliative Therapy for Hypermobile Ehlers-Danlos Syndrome
  • Proof of Concept Study Evaluating the Relative Efficacy and Safety of Concomitant Acetaminophen-Naproxen Sodium versus Acetaminophen/Hydrocodone and Naproxen in Postoperative Dental Pain
  • Proposed Risk Stratification of Drug Effect on Inducing Respiratory Depression
  • Prospective, Multicenter Study of Percutaneous Medial Branch PNS for the Treatment of Chronic Axial Low Back Pain
  • Racial variations in healthcare resource use and expenditures in a population of Medicaid patients with knee/hip osteoarthritis
  • Real World Evidence Data from UK to support Treatment with Capsaicin 8% Topical System in Various Peripheral Neuropathic Pain Conditions.
  • Real World Evidence of Sustained Improvements Following Percutaneous PNS: A Retrospective Cross-Sectional Follow-Up Survey of 354 Patients
  • Reasons for Hesitating to Consult for Migraine Care: Results of the OVERCOME (US) Study
  • Repeat Dosing With Subcutaneous Methylnaltrexone: A Pooled Analysis in Patients With and Without Cancer
  • Retrospective Analysis of High concentration Capsaicin Topical System for the treatment of post amputation stump pain and phantom limb pain
  • Retrospective comparison of the effectiveness of buprenorphine versus baclofen for acute opiate withdrawal
  • Risk Stratification of Respiratory Depression With Buprenorphine Buccal Film Versus Oxycodone: Outcomes From a Phase 1 Placebo-Controlled Trial
  • SC Methylnaltrexone in Patients with Advanced Illness and OIC: The Impact of Baseline Laxative Use
  • Skeletal Muscle Spasms and Pain and Dysfunction
  • Suicide by Opioid
  • Sustained Benefits of 10 kHz Spinal Cord Stimulation for Painful Diabetic Neuropathy - 6-Month Randomized Controlled Trial Results
  • Symptoms and diagnosis of painful diabetic peripheral neuropathy: the patient’s experience
  • Termination of effect of long acting injectable naltrexone and related challenges
  • The Association between Opioid Use Disorder and Childhood Adverse Experiences
  • The Body Function, Activity Limitations, and Participation Restrictions of Individuals with Poly-Trauma Clinical Triad
  • The Disparate Definitions and Measures of Post-Operative Respiratory Depression
  • The effectiveness of an Audio-Visual-Stimulation device in managing Fibromyalgia
  • The effectiveness of thermal neuromodulation using precise heat in the treatment of chronic low back pain over 60 days. An in-home user trial.
  • The polysubstance overdose-death crisis
  • The problem of postoperative respiratory depression
  • The use of acupuncture to facilitate goal-setting in chronic pain management
  • Total Pain Burden in Patients With Treatment-resistant Migraine: Effects of Galcanezumab in the CONQUER Phase 3b Trial
  • Treatment of painful diabetic peripheral neuropathy: the patient’s experience
  • Ubrogepant Treatment When Pain Is Mild Increases the Likelihood of Achieving Pain Freedom in Participants Who Treated Migraine Attacks of Mild and Moderate or Severe Pain
  • Ubrogepant Was Safe and Well Tolerated in the Acute Treatment of Perimenstrual Migraine Attacks
  • Ultrasound-Guided Dorsal Penile Blocks as an Effective Form of Analgesia for Circumcision
  • Update on In Vivo Testing of NTM-006 (formerly JNJ-10450232), a Novel Orally-Active Non-Opioid Analgesic: CFA and Paw Edema
  • Update on In Vivo Testing of NTM-006 (formerly JNJ-10450232), a Novel Orally-Active Non-Opioid Analgesic: Neuropathic Pain Model
  • What Patients Report Being Discussed During Their Most Recent Visit for Headache in Primary Care: Association with Being Diagnosed with Migraine
  • Monday, September 6, 2021
  • 6:00pm – 8:00pm
    PAINWeek 101
  • Tuesday, September 7, 2021
  • 7:30am – 8:20am
    Casting a Wider Net: Using Focused Acceptance & Commitment Therapy in Primary Care
  • 7:30am – 8:20am
    Prime Time or Too Soon? – Pharmacogenetics in Pain Management
  • 7:30am – 8:20am
    Treatment Algorithm for Managing Chronic Back Pain in the Elderly Population
  • 8:00am – 5:00pm
    Industry Supported Satellite Event
  • 8:30am – 9:30am
    Breakfast Product Theater, Disease Awareness, Medical Information (PDM) Program
  • 9:40am – 10:30am
    Calming the Storm: Adding PTSD Treatment to Your Pain Practice
  • 9:40am – 10:30am
    Interventional Options for Refractory Migraine and Cervicogenic Headaches
  • 9:40am – 10:30am
    Neurogenic Thoracic Outlet Syndrome
  • 9:40am – 10:30am
    Taming of the Spew! Managing Opioid-Induced Nausea and Vomiting
  • 10:30am – 11:00am
    Break
  • 11:00am – 11:50am
    “Doctor, I Have a Pain Between L4 and L5”: Dealing with False Positives and Google Dx
  • 11:00am – 11:50am
    Pink Elephant: Is Alcohol a Pain Panacea or a Problem?
  • 11:00am – 11:50am
    See, Be, Deceived…or Relieved? Evaluating CBD for Pain Management
  • 12:30pm – 1:30pm
    Lunch Product Theater, Disease Awareness, Medical Information (PDM) Program
  • 1:40pm – 2:30pm
    Post-Surgical Neuralgia: Diagnosis and Treatment
  • 1:40pm – 2:30pm
    Tales of Pain Self-Management Workshop: The Who, What, Why, and How!
  • 1:40pm – 2:30pm
    The Dog Ate My Homework: A Guide to Avoiding Relapse and Maintaining Adherence
  • 2:40pm – 3:30pm
    Apocalypse Now…or Later? Chronic Pain After COVID-19
  • 2:40pm – 3:30pm
    Implementing a New Pain Coach Education Service in an Academic Medical Center During the COVID Pandemic
  • 2:40pm – 3:30pm
    Updates on Complex Regional Pain Syndrome
  • 3:40pm – 4:30pm
    Afternoon Break Product Theater, Disease Awareness, Medical Information (PDM) Program. Refreshments Served.
  • 4:40pm – 5:30pm
    Night & Day: The Disabling Power of Sympathy/The Enabling Power of Empathy
  • 4:40pm – 5:30pm
    Osteoarthritic Joint Pain: Advances in Diagnosis and Treatment
  • 4:40pm – 5:30pm
    What's Psych Got to Do with Perioperative Pain Management?
  • 5:40pm – 6:30pm
    All in the Family: Their Role and Impact on Pain Management
  • 5:40pm – 6:30pm
    Everything's Coming Up Roses: How Pain Management Coaching Impacts Pain Outcomes
  • 5:40pm – 6:30pm
    Painful Conditions of the Upper Limb: Arm
  • Wednesday, September 8, 2021
  • 7:30am – 8:20am
    Acute Care for Patients Admitted to the hospital with Opioid Use Disorder
  • 7:30am – 8:20am
    Pain Pathways Made Simple
  • 7:30am – 8:20am
    The Clinical Pharmacist-Led Suboxone Clinic for Managing Comorbid Pain and OUD
  • 8:30am – 9:30am
    Breakfast Product Theater, Disease Awareness, Medical Information (PDM) Program
  • 9:40am – 10:30am
    An Integrative Pain Management Toolkit Initiative for Emergency Department and Hospital Patients
  • 9:40am – 10:30am
    Chronic Pain Assessment
  • 9:40am – 10:30am
    The Doors of Perception: Psychedelics in Pain Management
  • 9:40am – 10:30am
    Through the Lens of Experts: Meaningful Risk Mitigation and Patient Education
  • 10:30am – 11:00am
    Break
  • 10:30am – 11:20am
    Morning Break Product Theater, Disease Awareness, Medical Information (PDM) Program
  • 11:00am – 11:50am
    Chronic Pain in the Year of a Pandemic: Advanced Practice Provider Edition
  • 11:00am – 11:50am
    cute Post-Operative Pain: Current Practice, Novel & Upcoming Analgesic Options, and Drug Development
  • 11:00am – 11:50am
    The Ambient Zone: Sleep Induction Through Music Meditation
  • 12:30pm – 1:30pm
    Lunch Product Theater, Disease Awareness, Medical Information (PDM) Program
  • 1:40pm – 2:30pm
    Clinical Pearls: Unraveling the Secrets of Imaging Studies
  • 1:40pm – 2:30pm
    Reiki for Relaxation and Pain Relief in the Acute Care Setting
  • 1:40pm – 2:30pm
    The Potential Role of the Type 3 Adenosine Receptor Modulators (A3RMs) in the Management of Pain
  • 1:40pm – 2:30pm
    Who's Looking at You, Doc? A Rational Response to 2021 Perspectives on Opioid Prescribing
  • 2:40pm – 3:30pm
    Back to the Basics: The Role of Psychology in Pain
  • 2:40pm – 3:30pm
    So, You Checked the PDMP. Now What?
  • 2:40pm – 3:30pm
    Who Should Own Back Pain? An Interventional Pain Physician and a Physical Therapist Debate.
  • 3:40pm – 4:30pm
    The Role of a Once-Daily Intravenous Non-Opioid Option
  • 3:40pm – 4:30pm
    1 - Afternoon Break Product Theater, Disease Awareness, Medical Information (PDM) Program. Refreshments Served.
  • 4:40pm – 5:30pm
    The Referral Loop: A Guide for Frontline Clinicians on Electromyography and Nerve Conduction Studies
  • 4:40pm – 5:30pm
    Ain't No Honky-Tonk: Medical Cannabis for Pain Management
  • 4:40pm – 5:30pm
    Pain Therapeutics: Adjuvants and Nonopioid Analgesics
  • 5:40pm – 6:50pm
    Pain By Numbers: A+B=Z2
  • 6:50pm – 9:00pm
    Exhibit Hall Welcome Reception
  • Thursday, September 9, 2021
  • 7:30am – 8:20am
    NSAID Counterattack, Baby We're Back!
  • 7:30am – 8:20am
    OMG OMT! A Guide to Osteopathic Manipulative Treatment
  • 7:30am – 8:20am
    The Lesser of Three Evils? Untangling Somatic and Neurologic from Visceral Pain
  • 8:30am – 9:30am
    Breakfast Product Theater, Disease Awareness, Medical Information (PDM) Program
  • 9:40am – 10:30am
    A Face in the Crowd: Trigeminal Neuralgia and Atypical Facial Pain
  • 9:40am – 10:30am
    Bad Breadth: The Role of Bias, Stigma, and Social Determinants in Pain Care
  • 9:40am – 10:30am
    On Golden Pond: Geriatric Pain Management
  • 9:40am – 11:00am
    Digital Therapeutics: Technological Advances in Pain Medicine
  • 10:00am – 12:30pm
    Exhibit Hall Open (10:40a Raffle)
  • 10:30am – 11:00am
    Break
  • 10:30am – 11:20am
    Morning Break Product Theater, Disease Awareness, Medical Information (PDM). Refreshments served.
  • 11:00am – 11:50am
    7mm from Hell: Coping with Kidney Stone Pain
  • 11:00am – 11:50am
    Fire in the Lake: Raging War Over Endometriosis
  • 11:00am – 11:50am
    The Diagnosis in the Back of Your Head: Occipital Neuralgia vs Cervicogenic Headache
  • 11:00am – 11:50am
    The Future of Spine Surgery. Getting Smaller, Safer, and Better.
  • 12:30pm – 1:30pm
    Lunch Product Theater, Disease Awareness, Medical Information (PDM) Program
  • 1:40pm – 2:30pm
    Blurring the Lines: Pain and Demyelinating Conditions
  • 1:40pm – 2:30pm
    From the Ivory Tower: The Data-Driven Strategy CMS, Health Plans, and State Governments Use to Review a Provider’s Clinical Practice
  • 1:40pm – 2:30pm
    Tell Me Why It Hurts
  • 1:40pm – 2:30pm
    Vaping in the 21st Century: Is There a Safer Way to Deliver Drugs?
  • 2:30pm – 5:00pm
    Exhibit Hall Open (4:00p Raffle)
  • 2:40pm – 3:30pm
    Awkward Conversations: Managing Patients with Chronic Pain
  • 2:40pm – 3:30pm
    Health Literacy, Pain Medicine and COVID-19: Room for Improvement
  • 2:40pm – 3:30pm
    The Fight Has Just Begun: How COVID-19 Has Affected the Opioid Epidemic, Chronic Pain Treatment, and Mental Health.
  • 3:40pm – 4:30pm
    Afternoon Break Product Theater, Disease Awareness, Medical Information (PDM) Program. Refreshments served.
  • 4:40pm – 5:30pm
    A Feather or a Hammer? Pain and Movement Disorders
  • 4:40pm – 5:30pm
    Thunder Road: Navigating the Legal Weed Terrain for Pain Management
  • 4:40pm – 5:30pm
    Will the Real Fentanyl Please Stand Up?
  • 5:40pm – 6:30pm
    Hocus Pocus: What Muscle Relaxants Do and Don't Do
  • 5:40pm – 6:30pm
    The Dark at the Top of the Stairs: Addressing the Escalation of the Opioid Epidemic Due to COVID-19
  • 5:40pm – 6:30pm
    When Sitting Hurts: Unraveling Pudendal Neuralgia
  • 6:30pm – 8:30pm
    Scientific Poster Session
  • Friday, September 10, 2021
  • 7:30am – 8:20am
    Occupational Therapy and Biopsychosocial Pain Treatment: The “Other Therapy” You Never Knew Your Patients Needed
  • 7:30am – 8:20am
    Taking Private Interventional Pain Practices from Good to Great
  • 7:30am – 8:30am
    The L-Shaped Room: Challenges and Advances Managing Migraine
  • 8:30am – 9:30am
    Breakfast Product Theater, Disease Awareness, Medical Information (PDM) Program
  • 9:40am – 10:30am
    2+2 Before: Using New Math to Calculate Opioid Risk
  • 9:40am – 10:30am
    Sedated and Elated: Treatment Tactics for Refractory Agitation
  • 9:40am – 10:30am
    Surgical Consult: When Pain Management Is Contraindicated
  • 9:40am – 10:30am
    Who's on First? Neurologic and Psychiatric Management of Migraine
  • 10:00am – 12:30pm
    Exhibit Hall Open (10:40 Raffle)
  • 10:30am – 11:00am
    Break and Exhibit Hall Raffle
  • 10:40am – 12:00pm
    Poster/Podium Presentations
  • 11:00am – 11:50am
    Mastering Migraine: Examining the Therapeutic Spectrum for Optimal Patient Outcomes
  • 11:00am – 11:50am
    Rebalancing Pain Medicine: Improving Care Through a Wider Lens
  • 11:00am – 11:50am
    Sacroiliac Joint Dysfunction: Diagnosis, Treatment, and Emerging Therapy Options
  • 12:30pm – 1:30pm
    Industry Supported Lunch CME Symposium
  • 1:40pm – 2:30pm
    Diabetic Peripheral Neuropathy: Introducing New Interventional Options
  • 1:40pm – 2:30pm
    Tiny Habits for Pain Management: Evidence-based Behavior Change Models
  • 1:40pm – 2:30pm
    Urine Drug Testing: Meeting the Test of Medical Necessity Through Patient-Centered Care
  • 1:40pm – 3:30pm
    Back Pain: It's All About the Diagnosis
  • 2:30pm – 4:30pm
    Exhibit Hall Welcome Reception
  • 2:40pm – 3:30pm
    Electrical Tingles: Neuromodulation for the General Practitioner
  • 2:40pm – 3:30pm
    Elevator to the Gallows: Trigeminal Autonomic Cephalalgias (TACs)
  • 2:40pm – 3:30pm
    Physical Rehabilitation for Patients with Trauma
  • 3:40pm – 4:30pm
    Afternoon Break Product Theater, Disease Awareness, Medical Information (PDM) Program
  • 3:40pm – 4:30pm
    1 - Afternoon Break Product Theater, Disease Awareness, Medical Information (PDM) Program. Refreshments Served
  • 4:40pm – 5:30pm
    A Potpourri of Natural Opioids: Access, Safety, & Regulatory Responsibilities
  • 4:40pm – 5:30pm
    Melt in Your Body, Not in a Needle: A Review of ADF Opioids
  • 4:40pm – 5:30pm
    Working the Body: A Whole Health Perspective on Movement and Pain
  • 5:40pm – 6:30pm
    A Turning Wind: Women, Pain, and Achieving Health Equity
  • 5:40pm – 6:30pm
    No Kidding Around: Pediatric Trauma Care
  • 5:40pm – 6:30pm
    The Brain and Neuromodulation in Management of Osteoarthritis Pain
  • Saturday, September 11, 2021
  • 8:40am – 9:30am
    I Can't Hear You: The Association of Subclinical Hearing Loss with Cognitive Performance
  • 8:40am – 9:30am
    The Role of Regenerative Medicine in Low Back Pain
  • 9:40am – 10:30am
    Brave New World: Guidelines and Treatment Strategies for Sickle Cell Disease
  • 9:40am – 10:30am
    Diagnosing on the Spectrum: Alzheimer's Disease and Lewy Body Dementia
  • 9:40am – 10:30am
    New Advances in Spinal Cord Stimulation
  • 10:30am – 11:00am
    Break
  • 11:00am – 11:50am
    Diagnosing on the Spectrum: Alzheimer's Disease and Lewy Body Dementia`
  • 11:00am – 11:50am
    Dorsal Root Ganglion and Peripheral Nerve Stimulation: A More Targeted Approach for Nerve Pain
  • 11:00am – 11:50am
    Hard 8: Fake MUs! A Review of Atypical Opioid Medications
  • 11:50am – 12:30pm
    Break
  • 12:30pm – 1:20pm
    Examining Cannabinoids in the Epilepsy Treatment Spectrum
  • 12:30pm – 1:20pm
    How Low Can You Go? The Low-Down on Low Dose Analgesics
  • 12:30pm – 1:20pm
    The Future of Minimally Invasive Spine Treatments: Moving from Open Approaches to Less Invasive Procedures
  • 1:30pm – 2:20pm
    A Garden of Earthly Delights: Evaluating OTC Options for Pain Management
  • 1:30pm – 2:20pm
    Acupuncture for Pain Management